Sciwind Biosciences Initiates the First Patient Dosing of XW014 in P-I for the Treatment of Obesity and Type 2 Diabetes
Shots:
- The P-I clinical trial evaluates the safety, tolerability, food effect, PK, PD & early treatment effects of XW014 in patients (n=104) that are healthy or have type 2 diabetes for 6wks. across the US
- The single & multiple ascending dose study will evaluate the XW014 in healthy or diseased patients in which the multiple ascending dose group will include healthy individuals with elevated body mass index. Additionally, Sciwind expects to report the results from the P-I study by H2’23
- XW014 is an orally bioavailable small molecule GLP-1 receptor agonist that is being developed for the treatment of obesity & type 2 diabetes
Ref: PRNewswire | Image: Sciwind Biosciences
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
